Venetoclax is a new drug for the treatment of chronic lymphocytic leukemia (CLL). The synthesis methodS of Venetoclax and the key intermediates ,1-【[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl]methyl】piperazine and 3-nitro-4-【[(tetrahydro-2H-pyran-4-yl)methyl]amino】-benzenesulfonamide were summarized.It is proposed a good synthetic route which has high yield and is suitable for industrialized production,but the cost of Pd complex catalyst is expensive, so the cost needs to be cut down.
[ 1 ] 夏训明. 美国FDA批准Venclexta(venetoclax)治疗慢性淋巴细
胞白血病[J]. 广东药学院学报, 2016(2): 209.
[ 2 ] Bruncko M, Ding H, Doherty G, et al. Apoptosis-inducing agents
for the treatment of cancer and immune and autoimmune diseases:
WO, 2010138588[P]. 2010-12-02.